Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.

doi:10.1200/JCO.2021.39.15_suppl.e13023

HFCAS OpenIR

	Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.
	Shen, Xia-Bo ; Li, Guang-Liang ; Zheng, Ya-Bing ; Chen, Zhan-Hong ; Cao, Wen-Ming ; Shao, Xi-Ying ; Wang, Xiao-Jia
	2021-05-20
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e13023
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000708120300140
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126515
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Shen, Xia-Bo,Li, Guang-Liang,Zheng, Ya-Bing,et al. Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Shen, Xia-Bo.,Li, Guang-Liang.,Zheng, Ya-Bing.,Chen, Zhan-Hong.,Cao, Wen-Ming.,...&Wang, Xiao-Jia.(2021).Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Shen, Xia-Bo,et al."Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).